By Mill Chart
Last update: Dec 11, 2024
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) was identified as an affordable growth stock by our stock screener. NASDAQ:CPRX is showing great growth, but also scores well on profitability, solvency and liquidity. At the same time it seems to be priced reasonably. We'll explore this a bit deeper below.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:CPRX has achieved a 9 out of 10:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:CPRX has achieved a 8 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:CPRX has achieved a 8 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:CPRX, the assigned 8 is noteworthy for profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of CPRX for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
24.9
-0.06 (-0.24%)
Find more stocks in the Stock Screener
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.
Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a bullish technical setup, making it a stock to watch in the biotech sector.
CATALYST PHARMACEUTICALS (CPRX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors.
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive option for investors seeking affordable growth stocks in biotech.
A fundamental and technical analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is Poised for High Growth.
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A top pick for growth investors.